Ignite Creation Date:
2024-05-06 @ 5:43 PM
Last Modification Date:
2024-10-26 @ 2:34 PM
Study NCT ID:
NCT05408845
Status:
RECRUITING
Last Update Posted:
2024-02-07
First Post:
2022-06-02
Brief Title:
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment Chemotherapy With Docetaxel Plus Trastuzumab for Recurrent Metastatic or Unresectable HER2-Positive Salivary Gland Cancer
Sponsor:
Organization:
NRG Oncology